Alkem Laboratories Future Growth

Future criteria checks 1/6

Alkem Laboratories se prevé un crecimiento anual de los beneficios y los ingresos de 17.7% y 9.5% respectivamente. Se prevé que el BPA sea de grow en 19.2% al año. Se prevé que la rentabilidad de los fondos propios sea de 18.8% en 3 años.

Key information

17.9%

Earnings growth rate

19.5%

EPS growth rate

Pharmaceuticals earnings growth	18.9%
Revenue growth rate	9.6%
Future return on equity	18.8%
Analyst coverage	Good
Last updated	28 Mar 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BSE:539523 - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	178,760	28,949	21,509	N/A	1
3/31/2026	157,194	25,395	18,411	N/A	18
3/31/2025	142,562	21,903	15,632	N/A	19
3/31/2024	129,223	18,782	13,158	N/A	19
12/31/2023	126,344	15,732	N/A	N/A	N/A
9/30/2023	123,514	14,329	18,370	20,537	N/A
6/30/2023	119,906	11,433	N/A	N/A	N/A
3/31/2023	115,993	9,842	14,496	16,825	N/A
12/31/2022	111,805	10,208	N/A	N/A	N/A
9/30/2022	107,586	10,917	5,527	8,426	N/A
6/30/2022	104,792	13,051	N/A	N/A	N/A
3/31/2022	106,342	16,456	7,721	11,110	N/A
12/31/2021	103,425	17,780	N/A	N/A	N/A
9/30/2021	100,416	17,033	10,478	13,213	N/A
6/30/2021	96,044	16,311	N/A	N/A	N/A
3/31/2021	88,650	15,850	11,051	12,649	N/A
12/31/2020	87,218	15,338	N/A	N/A	N/A
9/30/2020	85,971	14,648	8,916	11,455	N/A
6/30/2020	84,984	13,636	N/A	N/A	N/A
3/31/2020	83,444	11,271	2,220	5,851	N/A
12/31/2019	81,484	11,057	N/A	N/A	N/A
9/30/2019	78,929	9,262	5,173	8,756	N/A
6/30/2019	75,478	8,098	N/A	N/A	N/A
3/31/2019	73,572	7,605	2,505	7,797	N/A
12/31/2018	70,157	6,602	N/A	N/A	N/A
9/30/2018	68,318	6,293	N/A	N/A	N/A
6/30/2018	67,788	6,955	N/A	N/A	N/A
3/31/2018	63,918	6,309	-4,177	2,660	N/A
12/31/2017	60,044	7,009	N/A	N/A	N/A
9/30/2017	57,285	7,626	N/A	N/A	N/A
6/30/2017	55,019	7,248	N/A	N/A	N/A
3/31/2017	56,875	8,920	N/A	4,711	N/A
12/31/2016	56,933	7,732	N/A	N/A	N/A
9/30/2016	54,992	7,267	N/A	N/A	N/A
6/30/2016	52,419	7,108	N/A	N/A	N/A
3/31/2016	49,248	7,416	N/A	7,258	N/A
12/31/2015	47,975	8,189	N/A	N/A	N/A
9/30/2015	44,556	7,227	N/A	4,023	N/A
6/30/2015	40,459	5,781	N/A	N/A	N/A
3/31/2015	37,434	3,916	N/A	3,255	N/A
3/31/2014	31,191	4,353	N/A	2,900	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: 539523(17.7% al año) es superior a la tasa de ahorro (6.7%).

Beneficios frente mercado: 539523Se prevé que los beneficios de la empresa (17.9% al año) crezcan menos que el mercado Indian (17.9% al año).

Beneficios de alto crecimiento: 539523Se prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: 539523(9.5% al año) se prevé que crezca más despacio que el mercado de Indian (10.5% al año).

Ingresos de alto crecimiento: 539523Se prevé que los ingresos de la empresa (9.5% al año) crezcan más despacio que 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): 539523Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (18.8%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Alkem Laboratories Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased by 15% to ₹4,936

Price target increased by 9.5% to ₹4,523

Price target increased by 7.5% to ₹3,956

Price target increased by 7.5% to ₹3,612

Consensus forecasts updated

Consensus EPS estimates fall by 11%

Recent updates

Price target increased by 15% to ₹4,936

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Consensus forecasts updated

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors

U.S. Food and Drug Administration Conducts Pre-Approval Inspection At Alkem Laboratories Limited Manufacturing Facility Located At St. Louis, Usa

Alkem Laboratories Limited Appoints Srinivas Singh as (Executive) Additional Director and Whole Time Director

Alkem Laboratories Limited Announces Retirement of Balmiki Prasad Singh as Executive Director

Consensus EPS estimates fall by 11%

Price target decreased to ₹3,357

Alkem Laboratories Limited Appoints Sujjain Talwar as an Additional Director, Designated as an Independent Director on the Board of Directors

Upcoming dividend of ₹4.00 per share

Alkem Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Less than half of directors are independent

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Announces Resignation of Ranjal Laxmana Shenoy as Non- Executive Independent Director

Price target decreased to ₹3,624

Alkem Laboratories Limited Proposes Final Dividend for Financial Year Ended 31 March, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹90m worth of stock

Executive Director recently bought ₹16m worth of stock

The Pharma Network LLC acquired 100% shares of S&b Pharma, Inc from Alkem Laboratories Limited (BSE:539523).

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹17m worth of stock

Insider recently sold ₹18m worth of stock

Second quarter 2022 earnings released: EPS ₹45.52 (vs ₹39.48 in 2Q 2021)

Insider recently sold ₹19m worth of stock

Price target increased to ₹3,793

Alkem Laboratories Limited Launches Ibuprofen and Famotidine Tablets in the United States

Upcoming dividend of ₹5.00 per share

Full year 2021 earnings released: EPS ₹133 (vs ₹94.26 in FY 2020)

Insider recently sold ₹31m worth of stock

Alkem Launches Perampanel Tablets in India Under the Brand Name "Perampil" for Treatment of Epilepsy

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2021, Payable on and from September 1, 2021

Insider recently sold ₹26m worth of stock

ALKEM Launches Brivaracetam in India Under the Brand Name Brivasure for Treatment of Epilepsy

Third quarter 2021 earnings released: EPS ₹37.72 (vs ₹31.95 in 3Q 2020)

Earnings beat expectations, revenue disappoints

Alkem Laboratories Limited to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: ₹2,968